IVA vs CLDX vs NKTR vs ABBV vs LLY vs KO

For growth investors, Eli Lilly and Company (LLY) is the stronger pick with 44.

7% revenue growth year-over-year, versus -78. 6% for Celldex Therapeutics, Inc. (CLDX). The Coca-Cola Company (KO) offers the better valuation at 27. 2x trailing P/E (25. 3x forward), making it the more compelling value choice. Analysts rate Inventiva S. A. (IVA) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, The Coca-Cola Company (KO) is the cheapest at 27.

2x versus AbbVie Inc. at 96. 1x. On forward P/E, AbbVie Inc. is actually cheaper at 16. 0x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Eli Lilly and Company wins at 1. 07x versus The Coca-Cola Company's 2. 26x — a reasonable growth-adjusted valuation.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +412.

1%, compared to -77. 6% for Nektar Therapeutics (NKTR). Over 10 years, the gap is even starker: LLY returned +1485% versus NKTR's -73. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus Inventiva S. A. 's 1. 59β — meaning IVA is approximately -893% more volatile than KO relative to the S&P 500. On balance sheet safety, Celldex Therapeutics, Inc. (CLDX) carries a lower debt/equity ratio of 0% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Eli Lilly and Company (LLY) is pulling ahead at 44.

7% versus -78. 6% for Celldex Therapeutics, Inc. (CLDX). On earnings-per-share growth, the picture is similar: Eli Lilly and Company grew EPS 96. 0% year-over-year, compared to -59. 2% for Celldex Therapeutics, Inc.. Over a 3-year CAGR, LLY leads at 31. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Eli Lilly and Company (LLY) is the more profitable company, earning 31.

7% net margin versus -172. 5% for Celldex Therapeutics, Inc. — meaning it keeps 31. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus -191. 6% for CLDX. At the gross margin level — before operating expenses — IVA leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Eli Lilly and Company (LLY) is the more undervalued stock at a PEG of 1. 07x versus The Coca-Cola Company's 2. 26x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, AbbVie Inc. (ABBV) trades at 16. 0x forward P/E versus 30. 9x for Eli Lilly and Company — 15. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IVA: 328. 6% to $16. 50.

In this comparison, ABBV (2.

9% yield), KO (2. 5% yield), LLY (0. 5% yield) pay a dividend. IVA, CLDX, NKTR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

53), 0. 5% yield, +1485% 10Y return). Inventiva S. A. (IVA) carries a higher beta of 1. 59 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LLY: +1485%, IVA: -71. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (IVA (Healthcare) and CLDX (Healthcare) and NKTR (Healthcare) and ABBV (Healthcare) and LLY (Healthcare) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: IVA is a small-cap quality compounder stock; CLDX is a small-cap quality compounder stock; NKTR is a small-cap quality compounder stock; ABBV is a large-cap quality compounder stock; LLY is a mega-cap high-growth stock; KO is a large-cap quality compounder stock. ABBV, LLY, KO pay a dividend while IVA, CLDX, NKTR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.